Efficacy of trastuzumab for HER-2 positive breast cancer in a real-life setting: A decade of experience under national treatment coverage regulations.

Camejo, Natalia; Castillo, Cecilia; Alonso, Rafael; Rivero, Emiliano; Mezquita, Camila; Rosich, Agustin; Dellacasa, Fiamma; Silveira, Luciana; Núñez, Jónathan Hernández; Delgado, Lucı́a

doi:10.1200/jco.2018.36.15_suppl.e18789

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, these monoclonal antibodies can mediate antibody-dependent cellular cytotoxicity (ADCC), engaging the immune system to recognize cancer cells coated with antibodies bound to the surface of the cell ( 129 ). Trastuzumab is a clinically approved anti-HER2 mAb which improves the overall survival of patients with HER2 + breast cancers ( 130 ). Pertuzumab targets a distinct epitope of HER2 and is another mAB used in the management of HER2 + breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

et al. 2022

View full text Add to dashboard Cite

Breast cancer is the most prevalent non-skin cancer diagnosed in females and developing novel therapeutic strategies to improve patient outcomes is crucial. The immune system plays an integral role in the body’s response to breast cancer and modulating this immune response through immunotherapy is a promising therapeutic option. Although immune checkpoint inhibitors were recently approved for the treatment of breast cancer patients, not all patients respond to immune checkpoint inhibitors as a monotherapy, highlighting the need to better understand the biology underlying patient response. Additionally, as radiotherapy is a critical component of breast cancer treatment, understanding the interplay of radiation and immune checkpoint inhibitors will be vital as recent studies suggest that combined therapies may induce synergistic effects in preclinical models of breast cancer. This review will discuss the mechanisms supporting combined approaches with radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Moreover, this review will analyze the current clinical trials examining combined approaches of radiotherapy, immunotherapy, chemotherapy, and targeted therapy. Finally, this review will evaluate data regarding treatment tolerance and potential biomarkers for these emerging therapies aimed at improving breast cancer outcomes.

show abstract

Section: Introductionmentioning

confidence: 99%